Company
Synairgen plc
Headquarters: Southampton, United Kingdom
Employees: 18
CEO: Mr. Richard Marsden
Market Cap
£12.0 Million
GBP as of Jan. 1, 2024
US$15.3 Million
Synairgen plc Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-à), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-à that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Synairgen plc has the following listings and related stock indices.
Stock: LSE: SNG wb_incandescent
Stock: OTC: SYGGF wb_incandescent
Stock: XSTU: OMY wb_incandescent